Previous Close | 0.00 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 0.00 - 0.00 |
52 Week Range | |
Volume | 0 |
Avg. Volume | N/A |
Market Cap | N/A |
Beta | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...
The addition of Bard will start paying off this year.
Becton Dickinson and Co (NYSE: BDX ) was initiated with a top-notch rating by KeyBanc Capital Markets Thursday. The Analyst KeyBanc analyst Matthew Mishan initiated coverage on Becton Dickinson with an ...
Rating Action: Moody's withdraws C.R. Global Credit Research- 02 Jan 2018. New York, January 02, 2018-- Moody's Investors Service, withdrew the Baa1 senior unsecured and Prime-2 short term ratings of C.R....
On December 28, Becton, Dickinson and Company (BDX), or BD, received clearance for its Bard (BCR) acquisition form MOFCOM (Ministry of Commerce of the People's Republic of China), but the approval is contingent ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)
FRANKLIN LAKES, N.J., Dec. 29, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (BCR), creating a new health care industry leader with approximately $16 billion in annualized revenue. The combined company is uniquely positioned to improve both the treatment of disease for patients and the process of care for health care providers. Additionally, Bard's strong product portfolio and innovation pipeline will increase BD's opportunities in fast-growing clinical areas, and the combination will enhance growth opportunities for the combined company in non-U.S. markets.
Favorable tidings on the regulatory front have boosted Becton, Dickinson and Company (BDX) lately. After the closure of the deal, the company will establish a new business segment.
NEW YORK , Dec. 28, 2017 /PRNewswire/ -- S&P MidCap 400 constituent Huntington Ingalls Industries Inc. (NYSE: HII) will replace C. R. Bard Inc. (NYSE: BCR) in the S&P 500, S&P SmallCap 600 constituent ...
Rating Action: Moody's downgrades Becton, Dickinson and Company to speculative grade. Global Credit Research- 28 Dec 2017. New York, December 28, 2017-- Moody's Investors Service, today downgraded Becton, ...
NutriSystem's (NTRI) Turbo Plans and South Beach Diet likely to witness an increase in customers.
FRANKLIN LAKES, N.J. , Dec. 28, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance ...
Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives C.R. Bard, Inc. (New Jersey) a score of 81. Our analysis is based on comparing C.R. Bard, Inc. (New Jersey) with the following peers – Boston Scientific Corporation, Teleflex Incorporated, Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., Medtronic plc, CryoLife, Inc., Hologic, Inc. and ... Read more (Read more...)
FRANKLIN LAKES, N.J. , Dec. 22, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's clearance ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)
Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing C.R. Bard, Inc. (New Jersey) with the following peers – Boston Scientific Corporation, Teleflex Incorporated, Becton, Dickinson and Company, AngioDynamics, Inc., Merit Medical Systems, Inc., Medtronic plc, CryoLife, Inc., Hologic, Inc. and CONMED Corporation (BSX-US, TFX-US, BDX-US, ANGO-US, MMSI-US, MDT-US, CRY-US, HOLX-US and CNMD-US). C.R. ... Read more (Read more...)
When C R Bard Inc (NYSE:BCR) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance ofRead More...
Jabil Inc. has tapped a health care industry financial expert for a soon-to-be-vacant seat on its board of directors. Christopher Holland, senior vice president and chief financial officer of C.R. Bard Inc., was nominated to stand for election to the Jabil board in January, a press release said. C.R. Bard (BCR) is a Murray Hill, New Jersey-based medical technology firm.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to C.R. Bard, Inc. (New Jersey) Here are 5 ETFs with the largest exposure to BCR-US. Comparing the performance and risk of C.R. Bard, Inc. (New Jersey) with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns ... Read more (Read more...)
The diabetes market is growing. And these stocks are poised to grow with it.